Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Tris Pharma, a specialty pharmaceutical company ... that it has been selected as an award winner ... 2014 Awards for Excellence competition in the Business ... of judges from SCORE (Counselors to America,s Small Business) ... honored at a gala event to be held on ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... stands to reason that the next beverage craze is ... Technology announced today that formulators can use Stress Relief ... ingredient used in the making of a beverage, including ... release for stress-generated energy, channeling that power into rapid ...
(Date:8/27/2014)... Cranford, NJ (PRWEB) August 27, 2014 ... and services – has once again shown superiority when ... trial sponsor by completing the ePRO portion of their ... results. The Japan-based pharma chose WriteResult’s digital writing ... IBS trials – the first to complete drew data ...
(Date:8/26/2014)... LOS ANGELES , Aug. 26, 2014  NeuroSigma, ... sciences company established to develop bioelectronic technologies, today announced ... S-1 with the U.S. Securities and Exchange Commission relating ... stock. The number of shares to be offered and ... yet been determined. Jefferies LLC will act ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... MINNEAPOLIS, Nov. 3 ATS Medical, Inc.,(Nasdaq: ... state-of-the-art cardiac,surgery products and services, today announced ... development of the ATS Forcefield(TM),technology. The animal ... regarding the inhibition of platelet adhesion on ...
... Journal published,an article on October 29th describing the ... and featuring quotes from,President and founder Dr. Timothy ... Transfusions: New Efforts to Recycle Blood and Treat ... part of the "The Informed Patient",series written by ...
Cached Biology Technology:Sunesis to Present at Upcoming Conferences 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2
(Date:8/28/2014)... most important crop-producing countries will be fully saturated with ... trends continue, according to a new study led by ... types can already be found in around half the ... advances at its current rate, scientists fear that a ... by pests within the next 30 years. , Crop ...
(Date:8/27/2014)... MADISON, Wis. The mechanical force that a single fungal ... seem vanishingly small, but it plays a heavy role in ... biology. In fact, it may not be too much of ... onto land without the ability to respond to the touch ... Jean-Michel An, a professor of agronomy at the University of ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... major component in the spice turmeric, when combined with ... and neck cancer cell growth, researchers with UCLA,s Jonsson ... widely used in South Asian and Middle Eastern cooking, ... attributed to its anti-inflammatory effects. Previous studies have shown ...
... and tissues in our bodies grow, develop and interact ... microbial pathogens that invade our bodies and cause infectious ... the methods of culturing and studying human cells have ... impermeable surfaces. While such 2-D culturing and modeling efforts ...
... of Leeds plant scientists has uncovered a snapshot of evolution ... million years ago led flowers to make male and female ... week in the Proceedings of the National Academy of ... a perfect example of how diversity stems from such genetic ...
Cached Biology News:Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 3The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4100-million-year-old mistake provides snapshot of evolution 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: